July 24, 2015

The Food and Drug Administration announced Friday that it approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and cirrhosis.

July 1, 2015

New exchange plan enrollees spent less on medications in the first quarter of 2015 compared with the same time a year ago, according to the third edition of the Express Scripts Exchange Pulse report released on Wednesday.

May 19, 2015

Walgreens on Tuesday joined the Chronic Liver Disease Foundation in offering free Hep-C tests this fall through January 2016. 

April 6, 2015

Public health exchange enrollees fill more prescriptions, but also opt more often for generics or 90-day fills, than their commercial plan counterparts. 


February 24, 2015

Mylan has been appointed as the exclusive India distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, by Gilead Sciences. 

December 23, 2014

Specialty pharmacy Diplomat Pharmacy has announced that it will stock Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets), which was approved Dec. 19 by the Food and Drug Administration.

December 22, 2014

The Food and Drug Administration has approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.

December 18, 2014

The CVS Health Research Institute released a first look at the comparative utilization of two new hepatitis C treatments in the weeks following their respective launches.

December 18, 2014

The Pharmaceutical Research and Manufacturers of America on Thursday released a new report, “Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones."

November 7, 2014

Janssen Therapeutics announced earlier this week that the Food and Drug Administration approved Olysio (simeprevir), a hepatitis C virus NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen. 

October 10, 2014

The Food and Drug Administration on Friday approved Gilead's Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus genotype 1 infection.

September 17, 2014

An analysis done by the CVS Health Research Institute provides insights regarding patients taking Sovaldi (sofosbuvir), a new and costly treatment for hepatitis C.

July 21, 2014

Commentary published online Monday addresses the controversy surrounding the high costs of new Hepatitis C virus treatments and implications for the growing specialty pharmacy market. 


June 9, 2014

Merck and Idenix Pharmaceuticals on Monday announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.

February 18, 2014

With new advances in treatment therapy now available for hepatitis C patients, Walgreens announced it is expanding access to Walgreens Connected Care hepatitis C program through its more than 100 hepatitis C-specialized pharmacies.

December 13, 2013

According to published reports, Express Scripts may be looking to start a "price war" among the makers of the latest generation of drugs for hepatitis C — which promise much shorter treatment times than standard therapies, but also cost significantly more — in an effort to bring down prices.

The stakes are certainly high. According to Centers for Disease Control and Prevention, there are 3.2 million people in the United States chronically infected with hepatitis C and hence at risk for liver cancer, and the CDC recommends that anyone born between 1945 and 1965 get tested for the virus.

December 13, 2013

Pharmacy benefit manager Express Scripts hopes to drive down the cost of new drugs to treat hepatitis C by pitting their manufacturers against each other, according to published reports.

December 10, 2013

Nearly all patients taking an experimental treatment for hepatitis C developed by AbbVie were cured, the drug maker said Tuesday.

December 6, 2013

The Food and Drug Administration has approved a new drug for hepatitis C made by Gilead Sciences, the drug maker said Friday.

November 25, 2013

The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

October 25, 2013

A Food and Drug Administration expert panel has recommended approval for a drug made by Johnson & Johnson for treating hepatitis C, the company said.

October 24, 2013

An experimental drug under development by Gilead Sciences for hepatitis C is safe and effective when combined with other treatments, according to a review posted on the Food and Drug Administration's website ahead of an expert panel meeting to take place Friday.

October 24, 2013

The Food and Drug Administration has granted breakthrough therapy designation to an experimental drug made by Merck for hepatitis C, the drug maker said.

June 21, 2013

A bill passed by the New York state legislature will require baby boomers visiting healthcare providers to be offered a hepatitis C screening.